Open Access

β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline‑induced pulmonary arterial hypertension

  • Authors:
    • Jiantao Sun
    • Jiali Cheng
    • Xue Ding
    • Jing Chi
    • Jiemei Yang
    • Weimin Li
  • View Affiliations

  • Published online on: November 22, 2019     https://doi.org/10.3892/etm.2019.8236
  • Pages: 489-498
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease with a high mortality rate. Previous studies have revealed the important function of the β3 adrenergic receptor (β3‑AR) in cardiovascular diseases, and the potential beneficial effects of numerous β3‑AR agonists on pulmonary vasodilation. Conversely, a number of studies have proposed that the antagonism of β3‑AR may prevent heart failure. The present study aimed to investigate the functional involvement of β3‑AR and the effects of the β3‑AR antagonist, SR59230A, in PAH and subsequent heart failure. A rat PAH model was established by the subcutaneous injection of monocrotaline (MCT), and the rats were randomly assigned to groups receiving four weeks of SR59230A treatment or the vehicle control. SR59230A treatment significantly improved right ventricular function in PAH in vivo compared with the vehicle control (P<0.001). Additionally, the expression level of β3‑AR was significantly upregulated in the lung and heart tissues of PAH rats compared with the sham group (P<0.01), and SR59230A treatment inhibited this increase in the lung (P<0.05), but not the heart. Specifically, SR59230A suppressed the elevated expression of endothelial nitric oxide and alleviated inflammatory infiltration to the lung under PAH conditions. These results are, to the best of our knowledge, the first to reveal that SR59230A exerts beneficial effects on right ventricular performance in rats with MCT‑induced PAH. Furthermore, blocking β3‑AR with SR59230A may alleviate the structural changes and inflammatory infiltration to the lung as a result of reduced oxidative stress.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun J, Cheng J, Ding X, Chi J, Yang J and Li W: β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline‑induced pulmonary arterial hypertension. Exp Ther Med 19: 489-498, 2020
APA
Sun, J., Cheng, J., Ding, X., Chi, J., Yang, J., & Li, W. (2020). β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline‑induced pulmonary arterial hypertension. Experimental and Therapeutic Medicine, 19, 489-498. https://doi.org/10.3892/etm.2019.8236
MLA
Sun, J., Cheng, J., Ding, X., Chi, J., Yang, J., Li, W."β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline‑induced pulmonary arterial hypertension". Experimental and Therapeutic Medicine 19.1 (2020): 489-498.
Chicago
Sun, J., Cheng, J., Ding, X., Chi, J., Yang, J., Li, W."β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline‑induced pulmonary arterial hypertension". Experimental and Therapeutic Medicine 19, no. 1 (2020): 489-498. https://doi.org/10.3892/etm.2019.8236